Scientists are using CRISPR technology to attempt to bring back extinct species.

CRISPR-Cas9 acts like molecular scissors, snipping DNA at exact spots to insert, delete, or tweak genes. Discovered in bacteria as an immune defense, it was adapted for eukaryotes in 2012 by Jennifer Doudna and Emmanuelle Charpentier, earning them the 2020 Nobel Prize[4][7]. For de-extinction, scientists sequence ancient DNA from fossils or preserved remains, then edit it into embryos of living relatives.

The process starts with extracting viable DNA—often from permafrost-preserved mammoths, where cells remain intact despite 10,000+ years[5]. Edited stem cells grow into viable embryos, implanted via IVF. By 2026, efficiency has soared, with 90%+ gene insertion success rates in lab mammals[8].

This tech isn't perfect; off-target edits pose risks, but AI-driven predictors now minimize errors to under 1%[9].

The woolly mammoth tops the list: Colossal Biosciences aims for hybrid calves by 2028, blending mammoth genes for thick fur and cold resistance into Asian elephant DNA[5][10]. These 'cold elephants' could repopulate Arctic tundra, trampling snow to preserve permafrost and curb methane release.

The dodo, extinct since 1662, is next—its DNA edited into Nicobar pigeons. Revived dodos might restore Mauritius forests by dispersing seeds[6]. The passenger pigeon, wiped out in 1914, targets band-tailed pigeons to revive American oak savannas[11].

Thylacine revival uses dunnart marsupials; early 2026 trials produced pouch young with tiger-like stripes[12].

De-extinct species could fill 'empty' niches: Mammoths as ecosystem engineers, compacting snow and fertilizing soil to boost carbon sequestration by 20% in tundras[13]. Dodos and pigeons enhance seed dispersal for plants long-lost.

2026 models predict mammoth reintroductions could increase Arctic biodiversity by 15%, aiding climate resilience[14]. Beyond revival, CRISPR saves endangered kin—like editing elephant genomes for ivory-free tusks[15].

Critics warn of 'Franken-animals': Hybrids may suffer health issues, and ecosystems could destabilize with novel predators[16]. Who owns revived species? Patents loom large.

Animal rights groups protest embryo experiments; IUCN deems pure de-extinction secondary to saving extant species[17]. Yet proponents argue it tests CRISPR for conservation wins.

By 2026, U.S. trials cleared FDA hurdles, but global treaties lag[18]. Public polls show 65% support if ecosystems benefit[19].

January 2026: First CRISPR-thylacine hybrid weaned successfully[12]. Colossal's mammoth embryo implanted in surrogate elephant, due Q4[10].

Funding surges: $500M+ invested globally; startups like Revive & Restore eye dire wolves next[20]. AI accelerates genome assembly 100x faster[9].

Timeline: Hybrids by 2028, purebreds by 2035? Success hinges on scaling IVF and habitats.